GPT and hepatotoxicity: While 7.4% of women in the Promoting Maternal and Infant Survival Everywhere (PROMISE) trial had grade ≥ 2 elevated ALT after initiating EFV–containing ART,[37] 10% of pregnant women living with HIV on TDF/3TC/EFV ART regimen in our study developed new hepatotoxicity events of grade ≥ 2 over the 3 years of follow-up.